SARTORIUS STEDIM BIOTECH (56S1.DE) Fundamental Analysis & Valuation

FRA:56S1 • FR0013154002

Current stock price

159.7 EUR
-2.6 (-1.6%)
Last:

This 56S1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. 56S1.DE Profitability Analysis

1.1 Basic Checks

  • 56S1 had positive earnings in the past year.
  • 56S1 had a positive operating cash flow in the past year.
  • 56S1 had positive earnings in each of the past 5 years.
  • In the past 5 years 56S1 always reported a positive cash flow from operatings.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • 56S1's Return On Assets of 3.28% is in line compared to the rest of the industry. 56S1 outperforms 43.75% of its industry peers.
  • With a Return On Equity value of 6.53%, 56S1 perfoms like the industry average, outperforming 43.75% of the companies in the same industry.
  • 56S1 has a Return On Invested Capital of 6.19%. This is comparable to the rest of the industry: 56S1 outperforms 56.25% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 56S1 is in line with the industry average of 7.18%.
  • The 3 year average ROIC (5.23%) for 56S1 is below the current ROIC(6.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.28%
ROE 6.53%
ROIC 6.19%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • The Profit Margin of 56S1 (8.99%) is better than 62.50% of its industry peers.
  • In the last couple of years the Profit Margin of 56S1 has declined.
  • Looking at the Operating Margin, with a value of 17.88%, 56S1 is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
  • 56S1's Operating Margin has declined in the last couple of years.
  • 56S1 has a Gross Margin (44.71%) which is comparable to the rest of the industry.
  • 56S1's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 17.88%
PM (TTM) 8.99%
GM 44.71%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. 56S1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 56S1 is destroying value.
  • Compared to 1 year ago, 56S1 has about the same amount of shares outstanding.
  • 56S1 has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for 56S1 has been reduced compared to a year ago.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • 56S1 has an Altman-Z score of 3.57. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
  • 56S1 has a Altman-Z score of 3.57. This is amongst the best in the industry. 56S1 outperforms 81.25% of its industry peers.
  • 56S1 has a debt to FCF ratio of 7.10. This is a slightly negative value and a sign of low solvency as 56S1 would need 7.10 years to pay back of all of its debts.
  • 56S1 has a Debt to FCF ratio of 7.10. This is comparable to the rest of the industry: 56S1 outperforms 50.00% of its industry peers.
  • 56S1 has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • 56S1 has a better Debt to Equity ratio (0.49) than 68.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 7.1
Altman-Z 3.57
ROIC/WACC0.66
WACC9.34%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.3 Liquidity

  • A Current Ratio of 1.03 indicates that 56S1 should not have too much problems paying its short term obligations.
  • 56S1's Current ratio of 1.03 is on the low side compared to the rest of the industry. 56S1 is outperformed by 68.75% of its industry peers.
  • 56S1 has a Quick Ratio of 1.03. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.58, 56S1 is doing worse than 68.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.58
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. 56S1.DE Growth Analysis

3.1 Past

  • 56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.71%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 1.13% on average over the past years.
  • Looking at the last year, 56S1 shows a small growth in Revenue. The Revenue has grown by 4.43% in the last year.
  • Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 9.21% on average per year.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%3.41%
Revenue 1Y (TTM)4.43%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.27%

3.2 Future

  • Based on estimates for the next years, 56S1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.07% on average per year.
  • The Revenue is expected to grow by 10.28% on average over the next years. This is quite good.
EPS Next Y17.04%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
EPS Next 5Y18.07%
Revenue Next Year7.37%
Revenue Next 2Y8.99%
Revenue Next 3Y9.53%
Revenue Next 5Y10.28%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. 56S1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 36.30 indicates a quite expensive valuation of 56S1.
  • Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 62.50% of the companies listed in the same industry.
  • 56S1's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.91.
  • 56S1 is valuated quite expensively with a Price/Forward Earnings ratio of 25.93.
  • 56S1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 62.50% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 21.99. 56S1 is around the same levels.
Industry RankSector Rank
PE 36.3
Fwd PE 25.93
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 56S1 indicates a rather expensive valuation: 56S1 more expensive than 81.25% of the companies listed in the same industry.
  • 56S1's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 42.22
EV/EBITDA 20.55
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • 56S1's earnings are expected to grow with 18.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.13
PEG (5Y)32.17
EPS Next 2Y18.3%
EPS Next 3Y18.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 56S1.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.44%, 56S1 is not a good candidate for dividend investing.
  • In the last 3 months the price of 56S1 has falen by -23.99%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 0.57, 56S1 has a dividend in line with its industry peers.
  • With a Dividend Yield of 0.44, 56S1 pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.44%

5.2 History

  • On average, the dividend of 56S1 grows each year by 15.19%, which is quite nice.
Dividend Growth(5Y)15.19%
Div Incr Years0
Div Non Decr Years2
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1

5.3 Sustainability

  • 25.01% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
  • The dividend of 56S1 is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP25.01%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

56S1.DE Fundamentals: All Metrics, Ratios and Statistics

SARTORIUS STEDIM BIOTECH

FRA:56S1 (4/27/2026, 7:00:00 PM)

159.7

-2.6 (-1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-23
Earnings (Next)07-23
Inst Owners11.99%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.54B
Revenue(TTM)2.98B
Net Income(TTM)268.30M
Analysts84.21
Price Target227.25 (42.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.44%
Yearly Dividend0.69
Dividend Growth(5Y)15.19%
DP25.01%
Div Incr Years0
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.45%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)0.3%
Revenue beat(8)4
Avg Revenue beat(8)-0.72%
Revenue beat(12)5
Avg Revenue beat(12)-1.61%
Revenue beat(16)5
Avg Revenue beat(16)-1.81%
PT rev (1m)-8.14%
PT rev (3m)-8.11%
EPS NQ rev (1m)-1.45%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.14%
EPS NY rev (3m)-3.5%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-1.2%
Valuation
Industry RankSector Rank
PE 36.3
Fwd PE 25.93
P/S 5.21
P/FCF 42.22
P/OCF 20.3
P/B 3.78
P/tB N/A
EV/EBITDA 20.55
EPS(TTM)4.4
EY2.76%
EPS(NY)6.16
Fwd EY3.86%
FCF(TTM)3.78
FCFY2.37%
OCF(TTM)7.87
OCFY4.93%
SpS30.66
BVpS42.21
TBVpS-3.03
PEG (NY)2.13
PEG (5Y)32.17
Graham Number64.6436 (-59.52%)
Profitability
Industry RankSector Rank
ROA 3.28%
ROE 6.53%
ROCE 8.11%
ROIC 6.19%
ROICexc 6.75%
ROICexgc 24.99%
OM 17.88%
PM (TTM) 8.99%
GM 44.71%
FCFM 12.34%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
ROICexc(3y)5.56%
ROICexc(5y)12.62%
ROICexgc(3y)18.67%
ROICexgc(5y)31.48%
ROCE(3y)6.85%
ROCE(5y)15.55%
ROICexgc growth 3Y-18%
ROICexgc growth 5Y-10.32%
ROICexc growth 3Y-31.81%
ROICexc growth 5Y-17.24%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
F-Score8
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 7.1
Debt/EBITDA 2.35
Cap/Depr 123.52%
Cap/Sales 13.32%
Interest Coverage 3.44
Cash Conversion 89.5%
Profit Quality 137.23%
Current Ratio 1.03
Quick Ratio 0.58
Altman-Z 3.57
F-Score8
WACC9.34%
ROIC/WACC0.66
Cap/Depr(3y)145.19%
Cap/Depr(5y)180.27%
Cap/Sales(3y)14.18%
Cap/Sales(5y)13.22%
Profit Quality(3y)157.37%
Profit Quality(5y)116.81%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%3.41%
EPS Next Y17.04%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
EPS Next 5Y18.07%
Revenue 1Y (TTM)4.43%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.27%
Revenue Next Year7.37%
Revenue Next 2Y8.99%
Revenue Next 3Y9.53%
Revenue Next 5Y10.28%
EBIT growth 1Y32.86%
EBIT growth 3Y-20.72%
EBIT growth 5Y1.39%
EBIT Next Year53.61%
EBIT Next 3Y26%
EBIT Next 5Y21.51%
FCF growth 1Y117.61%
FCF growth 3Y18.06%
FCF growth 5Y3.02%
OCF growth 1Y20.36%
OCF growth 3Y4.17%
OCF growth 5Y10.67%

SARTORIUS STEDIM BIOTECH / 56S1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.


Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.


What is the profitability of 56S1 stock?

SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.


What are the PE and PB ratios of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 36.3 and the Price/Book (PB) ratio is 3.78.


Can you provide the dividend sustainability for 56S1 stock?

The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10 and the dividend payout ratio is 25.01%.